Blood Sugar Control Peptides
Helps regulate blood glucose levels
Blood sugar control peptides regulate glucose metabolism through mechanisms that improve insulin secretion, enhance insulin sensitivity, or slow glucose absorption. GLP-1 agonists (semaglutide, tirzepatide, liraglutide) are the most clinically validated, with multiple FDA approvals for type 2 diabetes. They stimulate insulin release only when blood sugar is elevated (glucose-dependent action), which reduces the risk of hypoglycemia compared to older diabetes medications.
Beyond GLP-1 drugs, research peptides like MOTS-c and certain growth hormone peptides affect blood sugar through different pathways. Understanding which peptides raise versus lower blood sugar is important: MK-677 and GHRP-6 can increase fasting glucose, while GLP-1 agonists lower it. Choosing the wrong peptide for someone with blood sugar concerns can create problems rather than solving them.
This page collects every peptide on PeptideWiki tagged for blood sugar control. Browse individual profiles for mechanisms, dosing, and safety data.
Peptides (5)
Semaglutide
Semaglutide is a medication that mimics a natural fullness hormone (GLP-1) in the body. It is FDA-approved as Wegovy for weight management and Ozempic for type 2 diabetes, with significant effects on appetite control and blood sugar regulation.
Tirzepatide
Tirzepatide is a dual-action medication that activates both GIP and GLP-1 receptors, two key fullness and blood sugar hormones. It is FDA-approved as Mounjaro for type 2 diabetes and Zepbound for weight management, outperforming semaglutide in head-to-head trials.
Retatrutide
Retatrutide is an investigational medication that activates three hormone receptors (GIP, GLP-1, and glucagon) at the same time. Phase 2 trials showed up to 24% body weight loss at 48 weeks, and it is currently in Phase 3 development.
Liraglutide
Liraglutide is a medication that mimics a natural fullness hormone (GLP-1) in the body. It is FDA-approved as Victoza for type 2 diabetes and Saxenda for weight management, with an extensive record of clinical safety and effectiveness data.
MOTS-c
MOTS-c is a 16-amino-acid peptide produced by mitochondria (the energy centers of cells), encoded in mitochondrial DNA. It was the first mitochondrial peptide to enter clinical trials. Research focuses on metabolic health, exercise performance, and longevity, with natural levels declining with age.